Artesunate Injection IP

Name: Artesunate Injection IP
Brand: M Pharma Global
Price: 45 INR
Availability: InStock

Price 45 INR/ Vial

Get a Price/Quote

MOQ : 100 Vials

Artesunate Injection IP Specification

Origin of Medicine
India

Dosage Form
Injection

Indication
Severe malaria infection

Packaging Type
Box

Salt Composition
Artesunate

Drug Type
Allopathic

Ingredients
Artesunate

Physical Form
Injection

Function
Antimalarial

Recommended For
Treatment of severe malaria

Dosage
As directed by the physician

Dosage Guidelines
Follow the doctors prescription strictly

Suitable For
Adults and children

Storage Instructions
Store below 25C, protect from light

Registration Status
Manufactured under licence (India)

Usage
Hospital/institutional use only

Strength
120 mg per vial

Prescription Required
Yes

Brand Name
ARTHESUN-120

Administration Route
Intravenous or intramuscular injection

Artesunate Injection IP Trade Information

Minimum Order Quantity
100 Vials

Payment Terms
Cash in Advance (CID)

Supply Ability
1000 Vials Per Month

Delivery Time
5-7 Days

Main Domestic Market
All India

Artesunate Injection IP About

Discover ARTHESUN-120, the must-have antimalarial solution for hospitals and healthcare institutions tackling severe malaria. Engineered with formidable precision, this latest offering delivers valuable therapeutic action with transcendent reliability. Each vial contains 120 mg of Artesunate, ensuring affordable yet potent treatment for adults and children alike. Designed for intravenous or intramuscular administration, ARTHESUN-120 upholds quality and efficacy, manufactured under strict Indian licence. Its practical, allopathic composition emphasizes rapid action and patient safety, making it indispensable in hospital settings. Prescription required. Strictly follow professional dosage guidelines.

Features & Application of ARTHESUN-120 Artesunate Injection IP

ARTHESUN-120 boasts an advanced formulation for combating severe malaria in critical care environments. Its key feature is the high-efficacy 120 mg Artesunate per vial, suitable for both adults and children. Designed for intravenous or intramuscular administration, this injection stands out for its swift action and hospital-grade safety. Application includes hospital and institutional healthcare settings, where immediate, professional intervention is paramount in severe malaria cases. The packaging ensures sterility and protection from light, safeguarding medicine integrity.

ARTHESUN-120 Payment, Packaging, and Market Value

ARTHESUN-120 offers significant market value to domestic healthcare providers through competitive asking prices and reliable exchange practices. Packaging is securely done in protective boxes to maintain efficacy and ensure safe delivery. Our streamlined payment terms accommodate various institutional requirements, facilitating smooth transactions. The main domestic market for ARTHESUN-120 is India, where its prominence as a trusted exporter, supplier, and trader continuously rises, ensuring accessibility for hospitals and large medical facilities nationwide.

FAQ's of Artesunate Injection IP:

Q: How should ARTHESUN-120 Artesunate Injection IP be stored?

A: ARTHESUN-120 should be stored below 25C and protected from light to maintain its effectiveness and stability.

Q: What is the recommended dosage and administration route for ARTHESUN-120?

A: The dosage must be strictly as directed by a physician. It is administered intravenously or intramuscularly in a hospital or institutional setting.

Q: When is ARTHESUN-120 prescribed?

A: ARTHESUN-120 is prescribed for treating severe malaria infections, especially when rapid and potent antimalarial intervention is necessary.

Q: Where can ARTHESUN-120 be used?

A: ARTHESUN-120 is intended for use in hospitals or licensed healthcare institutions under professional supervision.

Q: What are the main benefits of using ARTHESUN-120 for malaria treatment?

A: The main benefits include its powerful antimalarial efficacy, swift action, reliable formulation, and suitability for both adults and children facing severe malaria.